Orphazyme board member on expected EMA rejection: "The next few days will be hell"

Arimoclomol has shown statistical significance as a treatment for Niemann-Pick type C, says Orphazyme Deputy Chairman of the Board Bo Jesper Hansen, who does not understand how the EMA can reject the candidate or why they have tightened up the rules for statistical significance.

Bo Jesper Hansen, deputy chair of the board, Orphazyme | Photo: Kåre Viemose

As well as holding the deputy chair position on the board of Orphazyme, Bo Jesper Hansen is something of a celebrity within the treatment of rare diseases, having also co-founded Swedish Orphan Biovitrium, Sobi.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs